Recruiting

Study of Drug Combination for Advanced Cancer Patients with Known Molecular Profile - FINPROVE Study

Verified siteRegistered drugNo placebo

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial studies the effectiveness of targeted anti-cancer drugs in patients with advanced cancer. The study aims to evaluate how well different medications work in treating cancers that have specific molecular profiles. The medications being tested include pemigatinib, trastuzumab, pertuzumab, vismodegib, apalutamide, abemaciclib, trametinib, atezolizumab, dabrafenib, entrectinib, olaparib, alectinib, regorafenib, vemurafenib, and tepotinib.

The study involves patients whose cancers have specific genetic changes that can be targeted by these medications. Before starting treatment, patients must undergo molecular testing of their tumor to determine if they have genetic changes that might make the treatment effective. This testing may include various methods such as fluorescence in situ hybridization, polymerase chain reaction, next generation sequencing, or immunohistochemistry.

The main goal is to measure how well patients respond to treatment after 16 weeks. Researchers will track how long the treatment works, monitor side effects, measure tumor response, and evaluate how long patients survive without their cancer getting worse. The study will also look at overall survival rates. Treatment will continue as long as patients are benefiting from it and not experiencing unacceptable side effects.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

Step 1
Initial evaluation
Your cancer tissue will be tested to determine its molecular profile using specialized laboratory tests like FISH, PCR, CGH, NGS, or IHC
A fresh tissue sample (biopsy) or blood sample will be collected for detailed testing. If a new biopsy is not safe to obtain, previously collected tissue may be used
Your overall health and organ function will be evaluated through blood tests and physical examination
Step 2
Treatment assignment
Based on your cancer's molecular profile, you will be assigned to receive one of the targeted anti-cancer medications
The medication may be given as tablets, capsules, injections, or infusions depending on the specific drug assigned
Step 3
Treatment period
You will receive the assigned medication for as long as it provides benefit
Regular evaluations will occur to monitor your response to treatment
The first major evaluation of treatment effectiveness will take place at 16 weeks after starting treatment
Step 4
Monitoring and follow-up
Your cancer's response to treatment will be measured using imaging scans
Side effects will be monitored and recorded, particularly any serious reactions
Blood tests will be performed regularly to check organ function
Treatment will continue until the cancer progresses or side effects become unmanageable
Step 5
Study completion
The study is planned to continue until December 2026
After completing treatment, you will need to use effective birth control for 4 months
Your survival and cancer status will continue to be monitored

Who can join the trial?

14 criteria

Must be at least 18 years old with confirmed advanced or metastatic cancer that is no longer responding to standard treatment, or when no standard treatment is available
Women who can become pregnant and men must use effective birth control (hormonal or barrier methods) or practice abstinence during the study and for 4 months after completing treatment
Must have an ECOG performance status of 0-2 (a scale measuring a person's ability to perform daily activities and self-care)
Must have adequate organ function, including:
- Sufficient white blood cell count
- Adequate hemoglobin levels
- Acceptable platelet count (except for blood cancer patients)
- Normal liver function tests
- Adequate kidney function
- Must have cancer that can be measured or evaluated through physical examination, imaging, or laboratory tests
- Must have results from tumor molecular testing (special tests that examine genetic changes in the tumor)
- Must have a tumor profile that suggests potential benefit from one of the targeted treatments in the study
- Must provide a new tumor sample (taken within 6 months before starting the study) or a liquid biopsy (blood test that looks for cancer cells or cancer DNA)
- Must be able to understand and sign an informed consent form
- For treatments taken by mouth, must be able to swallow pills and have no problems absorbing medications

Who cannot join the trial?

15 criteria

Age below 18 years or above 64 years
Any known allergies to the study medications
Participation in other clinical trials within the last 30 days
Presence of brain metastases (cancer that has spread to the brain)
Severe heart conditions or cardiovascular disease (heart and blood vessel problems)
Severe kidney or liver dysfunction
Active or uncontrolled infections
History of other cancers within the past 5 years (except for successfully treated non-melanoma skin cancer)
Pregnancy or breastfeeding
Unable to follow study procedures or attend scheduled visits
Major surgery within 4 weeks before starting the study
Immunodeficiency (weakened immune system) or active autoimmune diseases
Mental conditions that could interfere with study participation
Life expectancy less than 16 weeks
Uncontrolled high blood pressure

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Helsinki University Central Hospital
Verified
Helsinki, Finland
Oulu University Hospital
Verified
Oulu, Finland
Pirkanmaan hyvinvointialue
Verified
Tampere, Finland

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting

Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Based on the provided data, I cannot identify any specific medications or therapies to list, as the trial information doesn't contain details about individual treatments. The trial appears to be a Finnish study focused on targeted anti-cancer drugs, but specific medications are not mentioned in the source data. Without concrete information about the medications or therapies used in the trial, I cannot provide detailed descriptions of the treatments involved.

What is already known about the treatment

Since no specific medications are mentioned in the provided trial data, I cannot create medication descriptions. The data only shows that this is a Finnish clinical trial focused on targeted anti-cancer drugs for advanced cancers with known molecular profiles, but doesn't list any specific medications. To provide medication descriptions in the requested format, I would need information about specific drugs being tested in the trial. If you can provide the names of medications used in this trial, I can create descriptions following the format: Medication Name – description in a single paragraph covering administration, status, indications, mechanism of action, and classification.

Investigated diseases

Advanced Cancer - A condition where cancer cells have spread beyond their original location to other parts of the body. It develops when cancer cells break away from the primary tumor and travel through the bloodstream or lymphatic system to form new tumors in other organs or tissues. The process of cancer spreading is called metastasis, and these new tumor sites are called metastases. Advanced cancer typically involves multiple areas of the body and represents a later stage of the disease progression. The behavior of advanced cancer varies depending on the type of original cancer and which organs are affected.